Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumors, NET”

154 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 154 results

Early research (Phase 1)Looking for participantsNCT06479811
What this trial is testing

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Who this might be right for
Head and Neck TumorsKidney CancersSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI) 120
Not applicableUnknownNCT05268952
What this trial is testing

Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

Who this might be right for
Neuroendocrine Tumors
University Hospital, Antwerp 100
Very early researchActive Not RecruitingNCT05111509
What this trial is testing

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

Who this might be right for
Neuroendocrine Tumor Grade 2Neuroendocrine Tumor Grade 1
Yusuf Menda 20
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Not applicableUnknownNCT04444401
What this trial is testing

Registry on NEN Patients and COVID-19

Who this might be right for
Neuroendocrine TumorsCOVID-19
European Institute of Oncology 50
Post-approval studies (Phase 4)Ended earlyNCT04140409
What this trial is testing

Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Who this might be right for
Neuroendocrine TumorsCarcinoid Syndrome
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 10
Very early researchLooking for participantsNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Early research (Phase 1)Looking for participantsNCT05053854
What this trial is testing

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Who this might be right for
Neuroendocrine Tumors
Peter MacCallum Cancer Centre, Australia 24
Not applicableActive Not RecruitingNCT03583528
What this trial is testing

DOTATOC PET/CT for Imaging NET Patients

Who this might be right for
Neuroendocrine TumorsInsulinomaGastrinoma+13 more
British Columbia Cancer Agency 800
Testing effectiveness (Phase 2)Looking for participantsNCT06505395
What this trial is testing

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Who this might be right for
Gastrointestinal Neuroendocrine Pancreatic Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 90
Testing effectiveness (Phase 2)Ended earlyNCT04579679
What this trial is testing

Open-Label Surufatinib in European Patients With NET

Who this might be right for
Neuroendocrine TumoursNeuroendocrine Tumour of the LungSmall Intestinal NET
Hutchmed 78
Testing effectiveness (Phase 2)Looking for participantsNCT06943521
What this trial is testing

MT-4561 in Patients With Various Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more
Tanabe Pharma America, Inc. 27
Large-scale testing (Phase 3)Active Not RecruitingNCT05050942
What this trial is testing

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Who this might be right for
Gastro-enteropancreatic Neuroendocrine Tumor
Camurus AB 332
Not applicableUnknownNCT05448157
What this trial is testing

68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET

Who this might be right for
Neuroendocrine Tumor CarcinoidNeuroendocrine Tumor of PancreasGep Net
European Institute of Oncology 20
Testing effectiveness (Phase 2)Study completedNCT00363051
What this trial is testing

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Who this might be right for
Islet Cell CarcinomaNeuroendocrine CarcinomaNeuroendocrine Tumor+1 more
Novartis Pharmaceuticals 160
Testing effectiveness (Phase 2)Study completedNCT02936323
What this trial is testing

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Who this might be right for
Neuroendocrine TumorsCarcinoma, Small Cell LungNeuroendocrine Carcinoma
Tarveda Therapeutics 89
Testing effectiveness (Phase 2)WithdrawnNCT04276597
What this trial is testing

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Who this might be right for
Pulmonary Neuroendocrine NeoplasmPheochromocytomaParaganglioma+7 more
Excel Diagnostics and Nuclear Oncology Center
Very early researchActive Not RecruitingNCT06148636
What this trial is testing

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine Tumor of the LungNeuroendocrine Tumor Grade 1+2 more
David Bushnell 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05289856
What this trial is testing

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Who this might be right for
Cancer
Johannes Gutenberg University Mainz 30
Not applicableStudy completedNCT06853457
What this trial is testing

A Transfer Learning Radiomics Model for Predicting Response to Initial Transarterial Embolization in Patients with Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases

Who this might be right for
Neuroendocrine Tumors, NET
First Affiliated Hospital, Sun Yat-Sen University 257
Load More Results